ProQR Therapeutics N.V. (PRQR) Reaches $2.95 Low on Dec, 7; Usg (USG) Sentiment Is 0.62

December 7, 2017 - By Ellis Scott

The stock of ProQR Therapeutics N.V. (NASDAQ:PRQR) reached all time low today, Dec, 7 and still has $2.68 target or 9.00% below today’s $2.95 share price. This indicates more downside for the $93.99 million company. This technical setup was reported by Barchart.com. If the $2.68 PT is reached, the company will be worth $8.46 million less. The stock increased 1.72% or $0.05 during the last trading session, reaching $2.95. About 26,276 shares traded. ProQR Therapeutics N.V. (NASDAQ:PRQR) has risen 37.60% since December 7, 2016 and is uptrending. It has outperformed by 20.90% the S&P500.

USG Corporation, through its subsidiaries, makes and sells building materials worldwide. The company has market cap of $5.17 billion. The companyÂ’s Gypsum segment makes and markets gypsum and related products to construct walls, ceilings, roofs, and floors of residential, commercial, and institutional buildings, as well as for various industrial applications. It has a 12.15 P/E ratio. This segment offers gypsum panels, as well as joint compounds, corner beads, joint tapes, and plasters for wallboard joints finishing under the Sheetrock brand; cement board under the Durock brand; backerboard that includes abuse-resistant interior wall panels, tile backer boards, and flooring underlayments under the Fiberock brand; poured gypsum flooring systems under the Levelrock brand; roof boards under the Securock brand; and air-water barrier system and industrial gypsum under the ExoAir 430 brand.

Analysts await USG Corporation (NYSE:USG) to report earnings on February, 7. They expect $0.40 EPS, down 9.09% or $0.04 from last year’s $0.44 per share. USG’s profit will be $54.58M for 23.67 P/E if the $0.40 EPS becomes a reality. After $0.47 actual EPS reported by USG Corporation for the previous quarter, Wall Street now forecasts -14.89% negative EPS growth.

Ratings analysis reveals 33% of USG’s analysts are positive. Out of 6 Wall Street analysts rating USG, 2 give it “Buy”, 1 “Sell” rating, while 3 recommend “Hold”. The lowest target is $29.0 while the high is $36.0. The stock’s average target of $32.25 is -14.84% below today’s ($37.87) share price. USG was included in 6 notes of analysts from August 26, 2016. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, September 13. The rating was downgraded by Northcoast on Wednesday, August 31 to “Neutral”. Wedbush maintained the stock with “Neutral” rating in Thursday, October 27 report. Bank of America initiated the stock with “Buy” rating in Friday, September 23 report. Barclays Capital initiated the shares of USG in report on Friday, January 6 with “Underweight” rating. Citigroup initiated the shares of USG in report on Friday, August 26 with “Neutral” rating.

Ecofin Ltd holds 11.19% of its portfolio in USG Corporation for 43.80 million shares. Dudley & Shanley Llc owns 1.15 million shares or 6.9% of their US portfolio. Moreover, Greylin Investment Mangement Inc has 6.14% invested in the company for 917,275 shares. The Oklahoma-based Asset Management Advisors Llc has invested 5.37% in the stock. Shayne & Co. Llc, a Tennessee-based fund reported 197,113 shares.

The stock increased 1.50% or $0.56 during the last trading session, reaching $37.87. About 172,410 shares traded. USG Corporation (USG) has risen 0.17% since December 7, 2016 and is uptrending. It has underperformed by 16.53% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>